Imatinib: Chemical Structure, Pharmacology and Adverse Effects

Mojtaba Akhtari (Editor)
Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

Ihab Elhemaidi (Editor)
Princess Noorah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia

Series: Pharmacology – Research, Safety Testing and Regulation, Cancer Etiology, Diagnosis and Treatments
BISAC: MED071000

Clear

$179.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Imatinib has brought a revolution in the management of Chronic myelogenous leukemia (CML), a disease which had very limited therapeutic options including allogeneic hematopoietic stem cell transplantation and interferon-alpha 10 years ago. The clinical success of imatinib in CML and gastrointestinal tumors (GIST) has brought up a new paradigm in cancer therapy that has very broad potentials. Imatinib is active against a number of related tyrosine kinases, namely ABL, BCR-ABL, KIT, PFGFR and TEL. Now, as more than a decade has passed since the approval of Imatinib, and after the change of CML from a rapidly fatal disease to a more chronic and manageable disease, we wanted to have a look back at what we know about the drug and its effect on various body systems.

Its efficacy, side effects and how to manage its use in non-hematological malignancies is discussed in detail. Gathering all this information in one book will be of immense benefit for healthcare workers including physicians, pharmacists and nurses and this in turn will help them improve the care of their patients. It will also benefit pharmacists who are a source of clinical and pharmacological knowledge. For people undertaking research in the field of hemato-oncology or pharmacology, this will be a useful starting point for reviewing the literature. Imatinib is still being studied in patients in the clinic and laboratory models, and researchers are assessing the use of imatinib in other cancers. The editors have tried to allow information in book chapters to show different aspects and various view points on related issues. (Imprint: Nova Biomedical )

Preface

Chapter 1. The Chemical Structure, Pharmacology and Adverse Effects of Imatinib
(Giuseppe Visani, Federica Loscocco, Teresa Ricciardi, Paola Picardi, Sara Barulli, Barbara Guiducci and Alessandro Isidori, Hematology and Stem Cell Transplant Center, Pesaro, Italy)

Chapter 2. Clinical Pharmacokinetics of Imatinib and its Therapeutic Relevance
(Nicolas Widmer, Verena Gotta, Amina Haouala, Jaurès Blanc, Margaret von Mehren, Michel A. Duchosal, Serge Leyvraz, Chantal Csajka, Laurent A. Decosterd, and Thierry Buclin, Division de Pharmacologie clinique, Centre Hospitalier Universitaire Vaudois Hôpital de Beaumont, Lausanne, Switzerland)

Chapter 3. Imatinib Mesylate: Clinical Application and Management
(Shiksha Kedia, Manisha Pant, Pranab Sharma Acharya, Nilakantan Viswanathan, Meekoo Dhar and Vijaya Raj Bhatt, Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA)

Chapter 4. Practical Approach to the Hematologic Adverse Effects of Imatinib
(Nicholas A. Barber and Mojtaba Akhtari, Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA)

Chapter 5. Cutaneous Adverse Events Related To Treatment with Imatinib
(Paola Savoia and Paolo Fava, Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Turin, Torino, Italy)

Chapter 6. The Skeletal Effects of Imatanib Mesylate
(Susannah O’Sullivan and Andrew Grey, Department of Medicine, University of Auckland, Auckland, New Zealand)

Chapter 7. Effects of Tyrosine Kinase Inhibitors on Growth in Paediatric Patients
(Kate Vandyke and Andrew C.W. Zannettino, Myeloma Research Laboratory, Division of Haematology, Centre for Cancer Biology, SA Pathology and School of Medicine, University of Adelaide, Adelaide, Australia)

Chapter 8. Pro-apoptotic Effects of Imatinib on Pulmonary Artery Smooth Muscle Cells from Patients with Idiopathic Pulmonary Arterial Hypertension
(Kazufumi Nakamura, Satoshi Akagi, Kusano Kengo, Aiko Ogawa, Hiromi Matsubara and Hiroshi Ito, Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan)

Chapter 9. Secondary Molecular Targets of Imatinib in Cancer Cells
(Germana Rappa and Aurelio Lorico, Cancer Research Program, Roseman University of Health Sciences, Las Vegas, NV, USA)

Chapter 10. Activity of Imatinib Mesylate in Metastatic Melanoma
(Paolo Savoia and Paolo Fava, Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Turin, Torino, Italy)

Chapter 11. Imatinib Mesylate for Advanced Melanoma Harboring c-KIT Mutations: New Treatment Selection?
(Jun Guo, Department of Melanoma and Renal Cancer, Peking University Cancer Hospital and Institute, Peking, China)

Index

You have not viewed any product yet.